Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fospropofol disodium + sufentanil
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Fospropofol disodium + sufentanil is a combination anesthetic regimen consisting of a water-soluble prodrug of propofol and a potent opioid analgesic. Fospropofol disodium is metabolized by alkaline phosphatases to its active moiety, propofol, which acts as a positive allosteric modulator of the GABA-A receptor to induce sedation and anesthesia. Sufentanil is a highly potent mu-opioid receptor agonist that provides intense analgesia. This combination is primarily investigated for procedural sedation and general anesthesia induction, particularly in settings like ureteroscopic lithotripsy for urinary calculi, where it is evaluated for patient satisfaction and hemodynamic stability compared to standard propofol-based regimens.
- Other names
- fospropofol + sufentanil
02
Targets
MOR (Mu opioid receptor)ALP (Alkaline phosphatase)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on fospropofol disodium + sufentanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fospropofol disodium + sufentanil.